| Patient | Frida Kahlo |
|---|---|
| Date of birth | 1989-07-06 |
| Identifiers | MRN HR-NI011-SYN; SSN (made up) 000-11-4390 |
| Document date | 2026-10-01 |
| Author | Marisol Ortega, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Two-week chronic pain follow-up on the day of the rehabilitation consultation. [S]
Ms. Kahlo returns two weeks after her first visit, on the day of her physical medicine and rehabilitation consultation. The rehabilitation plan starts physical therapy twice a week with graded exercise, core and hip strengthening, and aquatic therapy, with a shoe lift for her shorter right leg; her first session is today. She has taken duloxetine 30 mg daily for two weeks. It caused mild nausea for the first few days, which has passed, and no dizziness, sweating, or sleep change. She takes acetaminophen 1 g three times a day and uses the diclofenac gel on her ankle, which makes standing easier. She still takes no more than four oxycodone tablets a day and has needed no early refills. The burning in her right leg is a little less at night. She can stand at the easel for about 15 minutes before the pain makes her sit. She has agreed to a first small reduction in her oxycodone dose at the four-week visit, provided her function holds, and asks that the taper stay slow. [S]
| Element | Detail |
|---|---|
| Rehabilitation | Consultation today; physical therapy twice weekly starts today; shoe lift prescribed |
| Duloxetine 30 mg | Two weeks; brief early nausea, now gone |
| Opioid use | No more than four oxycodone tablets a day; no early refills |
| Function | Stands at the easel for about 15 minutes |
| Taper | Agrees to a first small reduction at the four-week visit |
| PEG | 7.0, from 7.3 at intake |
| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | No drowsiness, fever, or weight change |
| Gastrointestinal | Negative | Nausea gone; no constipation; bowel habit unchanged |
| Musculoskeletal | Positive | Constant low back and pelvic pain; right ankle pain on standing; no falls |
| Neurological | Positive | Burning in the right leg, a little less at night; no new weakness or numbness; no bladder or bowel control change |
| Psychiatric | Positive | Frustrated at times by pain; no thoughts of self-harm |
5 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Oxycodone 10 mg oral tablet, one tablet every 6 hours as needed for pain, no more than four a day (60 MME a day) | One tablet by mouth every 6 hours as needed for pain; no more than 4 tablets a day | Oral route | 2024-03-04 to 2026-10-15 | completed | S |
| Duloxetine 30 mg delayed-release oral capsule, one capsule daily | One capsule by mouth daily | Oral route | 2026-09-17 to 2026-10-01 | completed | S |
| Duloxetine 60 mg delayed-release oral capsule, one capsule daily | One capsule by mouth daily | Oral route | 2026-10-01 | active | S |
| Acetaminophen 500 mg oral tablet, two tablets three times daily | Two tablets by mouth three times daily; no more than 3,000 mg a day | Oral route | 2026-09-17 | active | S |
| Diclofenac sodium 1% topical gel, 2 g to the right ankle four times daily | Apply 2 g to the right ankle and foot four times daily | Topical route | 2026-09-17 | active | S |
| Cholecalciferol (vitamin D3) 2,000 units oral tablet, one tablet daily | One tablet by mouth daily | Oral route | 2026-09-17 | active | S |
| Naloxone 4 mg nasal spray, one spray into one nostril for suspected opioid overdose; may repeat in the other nostril | For suspected opioid overdose: one spray into one nostril and call 911; if there is no response after 2 to 3 minutes, give a second spray in the other nostril | Nasal route | 2026-09-17 | active | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-10-01 | Body height | 160 | cm | S |
| 2026-10-01 | Body weight | 50 | kg | S |
| 2026-10-01 | Body mass index (BMI) [Ratio] | 19.5 | kg/m2 | S |
| 2026-10-01 | Systolic blood pressure | 116 | mm[Hg] | S |
| 2026-10-01 | Diastolic blood pressure | 72 | mm[Hg] | S |
| 2026-10-01 | Heart rate | 80 | /min | S |
| 2026-10-01 | Respiratory rate | 14 | /min | S |
| 2026-10-01 | Body temperature | 36.6 | Cel | S |
| 2026-10-01 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-10-01 | Mean score [PEG] | 7 | {score} | S |
Vital signs recorded on 2026-10-01; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Alert and talkative; not sedated; pupils equal and normal in size |
| Back | Lumbar paraspinal tenderness; healed lumbar surgical scars |
| Right ankle | Bony enlargement and reduced motion; no effusion; foot turned outward |
| Neurological | Right leg weakness and reduced reflexes, unchanged from intake |
| Gait | Walks with a cane and a limp from the shorter right leg |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Chronic low back and pelvic pain after remote spinal and pelvic fractures and spinal surgery, with neuropathic features in the right leg; linked to the documented 1925 injuries | active | confirmed | G89.21 | S — Synthetic modern diagnosis linked to the documented injuries; the neuropathic interpretation is R. |
| Post-traumatic osteoarthritis of the right ankle and foot after multiple leg fractures and a foot dislocation | active | confirmed | M19.171 | S — Synthetic diagnosis confirmed on the synthetic ankle X-ray. |
| Right leg weakness, atrophy, and shortening after childhood poliomyelitis; a congenital spinal anomaly has been proposed retrospectively | active | provisional | B91 | S — Synthetic modern coding of the documented childhood diagnosis; the alternative remains R. |
| Long-term opioid therapy for chronic pain, 60 MME a day at intake | active | confirmed | Z79.891 | S — Synthetic modern medication status; not a historical assertion. |
| Vitamin D deficiency | active | confirmed | E55.9 | S — Synthetic finding from the baseline 25-hydroxyvitamin D. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Survey | PEG pain, enjoyment of life, and general activity score | Every visit | Completed today | 7.0, from 7.3 at intake |
| Survey | PHQ-9 depression score, with item 9 | Every 2 to 4 weeks during active treatment | Up to date | 8 at intake with item 9 scored 0; next at the four-week visit |
| Medication safety | Opioid benefits and harms: function, sedation, constipation, falls | Every visit during a taper; at least every 3 months | Completed today | No sedation, constipation, or falls; function slowly improving |
| Medication safety | Prescription drug monitoring program check | Before each opioid prescription; at least every 3 months | Up to date | Checked at intake: a single prescriber and no sedatives. No opioid prescription today |
| Laboratory | Urine drug test, with consent | Before long-term therapy, then at least annually | Up to date | At intake, consistent with the prescribed oxycodone only |
| Medication safety | Naloxone at home, with a family member trained | Offer when starting or continuing opioids; review each visit | Up to date | Dispensed at intake, with her spouse taught to use it |
| Medication safety | Concurrent benzodiazepines or other sedatives | Every visit | Completed today | None prescribed or taken |
| Medication safety | Duloxetine tolerance after starting | About 2 weeks after starting and after each dose change | Completed today | Brief nausea only; blood pressure 116/72. Increased to 60 mg |
| Laboratory | ALT on regular acetaminophen | Periodically when acetaminophen approaches 3 g a day | Up to date | 22 U/L at intake; recheck at the six-week review |
| Laboratory | CBC, creatinine, and blood pressure for chronic oral NSAID use | Every 6 to 12 months on oral NSAIDs | Not indicated | Topical diclofenac only; creatinine 0.72 at intake |
| Examination | Right ankle examination: range of motion, effusion, alignment | Every visit | Completed today | Bony enlargement and reduced motion; no effusion |
| Imaging | Right ankle radiograph | Only for diagnostic uncertainty, clinical change, or surgical planning | Not indicated | Done at intake; no routine surveillance imaging |
| Referral | Physical medicine and rehabilitation | Once, for a multimodal rehabilitation plan | Completed today | Seen today; physical therapy and a shoe lift |
| Referral | Cognitive behavioral therapy for chronic pain | Early in a multimodal plan | Referred | Referred today |
| Self-management | Exercise program adherence | Every visit | Completed today | Physical therapy twice weekly starts today, with home exercises |
| Laboratory | 25-hydroxyvitamin D | About 3 months after starting repletion | Due | 18 ng/mL at intake; recheck in about eleven weeks |
Goal progress:
Guideline basis: CDC Clinical Practice Guideline for Prescribing Opioids for Pain — United States, 2022 (2022); Noninvasive Treatments for Acute, Subacute, and Chronic Low Back Pain: A Clinical Practice Guideline From the American College of Physicians (2017); VA/DoD Clinical Practice Guideline for the Diagnosis and Treatment of Low Back Pain (2022); CMID: Clinical Monitoring Intelligence Database, osteoarthritis and depression monographs (2026)
Follow-up: Physical therapy twice weekly. Four-week chronic pain follow-up in two weeks for the first oxycodone reduction. Next scheduled visit 2026-10-15: four-week chronic pain follow-up with the first opioid dose reduction. [S]